First‐line crizotinib versus platinum‐pemetrexed chemotherapy in patients with advanced ROS1‐rearranged non‐small‐cell lung cancer

OBJECTIVES: Food and Drug Administration (FDA) approved crizotinib for advanced ROS1‐rearranged (ROS1+) non‐small‐cell lung cancer (NSCLC) patients due to a single‐arm study PROFILE 1001. However, there is no direct comparison between crizotinib and platinum‐pemetrexed chemotherapy. MATERIALS AND ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Lan, Qiang, Tan, Li, Ziming, Ding, Ding, Yu, Yongfeng, Lu, Shun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7221427/
https://www.ncbi.nlm.nih.gov/pubmed/32167664
http://dx.doi.org/10.1002/cam4.2972

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7221427/
https://www.ncbi.nlm.nih.gov/pubmed/32167664
http://dx.doi.org/10.1002/cam4.2972

Ejemplares similares